▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1478 by analyst upside · 2026-11-13
ABSI
Absci Corporation
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+62.2%
implied upside to consensus target
Current Price $9.13
Consensus Target $14.82
Bull Target $20.0
Bear Target $10.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
1
Sell
0
52-Week Low $2.24
52-Week High $12.54
YTD Return +153.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.79
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.24
52-Week High $12.54
Current Price $9.13
Bear Target $10.0
Bull Target $20.0
● Now $9.13 ● Target $14.82
TRADING DATA
Avg Volume 3.8M
YTD Return +153.0%
Analyst Count 11
Consensus Buy
Upside to Target +62.2%
Last Updated 2026-11-13

ANALYST SUMMARY

Absci Corporation (ABSI) is currently trading at $9.13 with a Wall Street consensus price target of $14.82, implying potential upside of 62.2% over the next 12 months. 11 analysts currently cover ABSI, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $10.0.

ABSI operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 153.0% year-to-date and is currently trading near the upper end of its 52-week range of $2.24 – $12.54.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ABSI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies ● Initiated
Buy 2026-10-29 50% win rate (6 calls)
Keybanc - Reiterated
Overweight → Overweight 2026-10-16 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-10-12 43% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-10-12 31% win rate (48 calls)
Needham reit
Buy → Buy 2026-09-23 20% win rate (5 calls)
LifeSci Capital ● Initiated
Outperform 2026-09-09 Building track record
BTIG - Reiterated
Buy → Buy 2026-09-08 38% win rate (8 calls)
Needham reit
Buy → Buy 2026-08-12 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
19/30
Consensus clarity
8/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →